Transcriptomic Analysis Reveals JAK2/MPL-Independent Effects of Calreticulin Mutations in a C. elegans Model

Ana Guijarro-Hernández1, Laura Eder-Azanza1, Cristina Hurtado1

  • 1Department of Biochemistry and Genetics, School of Sciences, University of Navarra, 31008 Pamplona, Spain.

Cells
|January 8, 2023
PubMed

Insights

This study introduces a new C. elegans model for studying Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). The model helps investigate CALR mutations independently of JAK2/MPL pathways, revealing new disease mechanisms.

Area of Science:

  • Molecular Biology
  • Genetics
  • Hematology

Background:

  • Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) involve complex molecular disturbances.
  • CALR mutations drive MPNs via non-canonical pathways, but research is limited by a lack of suitable experimental models.
  • Understanding JAK2/MPL-independent mechanisms of CALR mutations is crucial for MPN research.

Purpose of the Study:

  • To develop and validate a C. elegans model for studying JAK2/MPL-independent CALR mutation effects in MPNs.
  • To identify novel molecular mechanisms and pathways affected by CALR mutations.
  • To explore potential new therapeutic targets for MPNs.

Main Methods:

  • CRISPR/Cas9 gene editing introduced patient-like CALR mutations into C. elegans lacking JAK2 and MPL orthologs.
  • Whole-genome transcriptomic analysis was performed on engineered C. elegans.
  • Quantitative PCR (qPCR) validated key transcriptomic alterations.

Main Results:

  • Transcriptomic analysis revealed alterations in genes and processes relevant to MPN pathogenesis, independent of JAK2/MPL.
  • Identified novel pathways dysregulated by CALR mutations, including Hedgehog signaling and flh-3.
  • The observed alterations largely resulted from a loss of function of mutant calreticulin in C. elegans.

Conclusions:

  • The C. elegans model provides a novel platform for investigating JAK2/MPL-independent mechanisms of mutant calreticulin.
  • This model facilitates the study of previously unrecognized non-canonical effects of mutant calreticulin.
  • Further research in this model and validation in mammalian systems may uncover new therapeutic strategies for MPNs.